Related references
Note: Only part of the references are listed.A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas
Giovanni Rindone et al.
BLOOD ADVANCES (2023)
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma
Elif Karaca Atabay et al.
BLOOD (2022)
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma
Margret Merino et al.
PEDIATRIC BLOOD & CANCER (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
PDGF receptor mutations in human diseases
Emilie Guerit et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
Alison J. Moskowitz et al.
BLOOD (2021)
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Jing-Zhou Hou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway
Katie Lee et al.
BLOOD (2021)
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Punit Saraon et al.
ONCOGENE (2021)
Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified
Koen Debackere et al.
NATURE COMMUNICATIONS (2021)
Synergistic Drug Combinations Prevent Resistance in ALK plus Anaplastic Large Cell Lymphoma
Giulia Arosio et al.
CANCERS (2021)
FYN-TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma
Christine S. Moon et al.
NATURE CANCER (2021)
FER and FES tyrosine kinase fusions in follicular T-cell lymphoma
Koen Debackere et al.
BLOOD (2020)
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy
Elisa Bossi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial
Reiji Fukano et al.
CANCER SCIENCE (2020)
Tyrosine Kinase Receptors in Oncology
Jorge Esteban-Villarrubia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Liling Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
Martina Magni et al.
BRITISH JOURNAL OF CANCER (2019)
Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T-cell lymphoma expressing the ITK-SYK fusion gene
Lei-Lei Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Hematological malignancies and molecular targeting therapy
Akira Shimada
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma
Jayadev M. Umakanthan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Bruton Tyrosine Kinase Inhibitors Present and Future
Jan A. Burger
CANCER JOURNAL (2019)
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Qinlian Jiao et al.
MOLECULAR CANCER (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression
Narmeen N. Fathi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma
Rebeca Manso et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
Anita Kumar et al.
BLOOD ADVANCES (2018)
T-cell Receptor Signaling Activatesan ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy
Tianjiao Wang et al.
CLINICAL CANCER RESEARCH (2017)
STAT3 mutation impacts biological and clinical features of T-LGL leukemia
Antonella Teramo et al.
ONCOTARGET (2017)
Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas
A. Nicolae et al.
LEUKEMIA (2016)
Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma
Cristina Perez et al.
HAEMATOLOGICA (2015)
Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma
Cristina Perez et al.
HAEMATOLOGICA (2015)
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma
Juliet Fraser Gibson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients
Carlo Gambacorti Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway
P. P. Piccaluga et al.
LEUKEMIA (2014)
OPEN B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
D. L. Petersen et al.
LEUKEMIA (2014)
Angioimmunoblastic T-cell lymphoma in taiwan showed a frequent gain of ITK gene
Peir-In Liang et al.
PATHOLOGY (2014)
ITK/SYK Translocation in Angioimmunoblastic T-cell Lymphoma
Ayoma D. Attygalle et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Mature T-cell Lymphomagenesis Induced by Retroviral Insertional Activation of Janus Kinase 1
Tim Heinrich et al.
MOLECULAR THERAPY (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
New molecular insights into peripheral T cell lymphomas
Stefano A. Pileri et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas
Daniela Laimer et al.
NATURE MEDICINE (2012)
Anaplastic lymphoma kinase in human cancer
Antonella Barreca et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2011)
Crizotinib in Anaplastic Large-Cell Lymphoma
Carlo Gambacorti-Passerini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma
Konstanze Pechloff et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines
R. A. Wilcox et al.
LEUKEMIA (2010)
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
Thomas R. Webb et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
Alessandro Fornari et al.
HEMATOLOGICAL ONCOLOGY (2009)
Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas
A. L. Feldman et al.
LEUKEMIA (2008)
The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein
Mitsuru Okuwaki
JOURNAL OF BIOCHEMISTRY (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Gene expression analysis of Angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation
Pier Paolo Piccaluga et al.
CANCER RESEARCH (2007)
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
Pier Paolo Piccaluga et al.
CANCER (2007)
Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
Pier Paolo Piccaluga et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage
Jaouhar Mourali et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma
B Streubel et al.
LEUKEMIA (2006)
c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas
YS Choe et al.
LEUKEMIA & LYMPHOMA (2006)
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
R Piva et al.
BLOOD (2006)
Expression of platelet-derived growth factor receptor α in peripheral T-cell lymphoma not otherwise specified
PP Piccaluga et al.
LANCET ONCOLOGY (2005)
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
R Chiarle et al.
NATURE MEDICINE (2005)
Differential expression of protein kinase C isoenzymes related to high nitric oxide synthase activity in a T lymphoma cell line
G Gorelik et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
Share Paper
